Eric Klein, MD, discusses safety data with VERU-111 from a phase 2 trial that enrolled patients with metastatic castration-resistant prostate cancer that was presented during the 2021 Genitourinary Cancers Symposium.
Eric A. Klein, MD
Advertisement
Articles by Eric A. Klein, MD
Eric A. Klein, MD, discusses challenges with active surveillance in prostate cancer.
Eric A. Klein, MD, discusses the Oncotype DX test and how it is utilized to predict tumor aggressiveness in patients with prostate cancer.
Eric A. Klein, MD, discusses the utility of Oncotype DX Genomic Prostate Score in predicting outcomes in African American men with prostate cancer.
Eric A. Klein, MD, discusses the importance of providing genomic testing to patients with prostate cancer.
Advertisement
Latest Updated Articles
Dr. Klein on the Safety of VERU-111 in mCRPCPublished: February 17th 2021 | Updated:
Dr. Klein on the Importance of the Importance of Prognostic Genomic Assays in Prostate CancerPublished: May 20th 2020 | Updated:
Dr. Klein on Oncotype DX in Predicting Outcomes in African Americans With Prostate CancerPublished: May 21st 2020 | Updated:
Dr. Klein on Predicting Tumor Aggressiveness With Oncotype DX Test in Prostate CancerPublished: June 4th 2020 | Updated:
Dr. Klein on Challenges With Active Surveillance in Prostate CancerPublished: June 19th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Emerging Data With Oral SERDs Reframe Frontline and Post–CDK4/6 Decisions in ER+ Breast Cancer
2
Relacorilant Plus Nab-Paclitaxel Meets OS End Point of ROSELLA Trial in PROC
3
Sofi-Cel Earns FDA Breakthrough Therapy Designation in Heavily Pretreated R/R T-ALL and T-LBL
4
Treatment Individualization Is Increasingly Vital With T-DXd Poised to Enter Early-Stage HER2+ Breast Cancer Paradigm
5